Infinimmune, a biotechnology company pioneering antibody discovery and design, announced a collaboration with Merck, known as MSD outside of the United States and Canada, to apply Infinimmune’s human-first antibody discovery platform to identify and develop antibody candidates against multiple undisclosed targets designated by Merck.
